The oncology nutrition market was valued at USD 1.34 Billion in 2017 and is expected to reach USD 2.21 Billion by 2023, at a CAGR of 8.7% during the forecast period.

Factors such as the development of elemental formulas and product innovation in terms of non-GMO-based formulas present significant opportunities for the growth of oncology-based nutrition formulas.

The report analyzes the oncology nutrition market by type of cancer and region. Based on cancer type, the head and neck cancers segment accounted for the largest share of the market in 2017. Patients with head and neck cancers suffer from severe problems associated with oral nutritional intake. Thus, the enteral route is used for nutrition support. With the increasing number of such cancers cases, the uptake of tube feeding formulas has increased. Also, conditions such as severe mucositis, xerostomia, dysgeusia, and nausea & vomiting limit nutritional intake, adding to the adoption of oncology nutritional feeding formulas.

Geographically, the oncology nutrition market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2017, North America accounted for the largest share of this market. However, the Asia Pacific region is expected to witness the highest CAGR during the forecast period of 2018 to 2023. The growth of this segment can be attributed to the increased awareness and accessibility to advanced healthcare facilities, rising healthcare spending, large population base, and rapid improvements in the health insurance sector.

To know about the assumptions considered for the study, download the pdf brochure

The major players in the oncology nutrition market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B.Braun Melsungen AG (Germany). The other players in this market include Mead Johnson Nutrition Company (US), Hormel Foods (US), Meiji Holdings (Japan), Victus (US), and Global Health Products (US).